Sarepta Therapeutics, Inc.

SRPT

US8036071004

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 11/04/2026 am IST			5-day change	1st Jan Change
21.18 ^USD	-4.72%		-8.82%	-1.58%

07/04	RBC Adjusts Price Target on Sarepta Therapeutics to $19 From $18, Maintains Sector Perform Rating	MT
26/03	Deutsche Bank Raises Price Target on Sarepta Therapeutics to $14 From $12, Keeps Sell Rating	MT

Sarepta Therapeutics CEO Ingram to retire by year end

Published on 02/26/2026 at 10:54 am IST

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Sarepta Therapeutics, Inc.

07/04	RBC Adjusts Price Target on Sarepta Therapeutics to $19 From $18, Maintains Sector Perform Rating	MT
26/03	Deutsche Bank Raises Price Target on Sarepta Therapeutics to $14 From $12, Keeps Sell Rating	MT
26/03	Wedbush Raises Price Target on Sarepta Therapeutics to $35 From $29, Keeps Outperform Rating	MT
26/03	Health Care Up Amid Deal Activity -- Health Care Roundup	DJ
25/03	Top Midday Gainers	MT
25/03	Sarepta Therapeutics, Inc. - Special Call
25/03	Sarepta Therapeutics Announces First Clinical Data from Sirna Pipeline Targeting FSHD1 and DM1	CI
25/03	Sarepta Therapeutics' Early Trial Results of siRNA Treatments Show High Muscle Concentrations in Neuromuscular Diseases	MT
25/03	Sarepta announces first clinical data from sirna pipeline targeting FSHD1 and DM1	RE
19/03	Sarepta Therapeutics Plans to Submit Supplemental New Drug Applications for Amondys 45, Vyondys 53	MT
19/03	Sarepta Therapeutics Provides Regulatory Update On Amondys 45 And Vyondys 53	CI
19/03	Taysha Gene Therapies, Inc. Appoints Brad Martin as Senior Vice President, Market Access and Value	CI
16/03	Sarepta Begins Enrollment in Study Evaluating Safety Regimen With Duchenne Therapy	MT
16/03	Sarepta announces that screening and enrollment are underway in Endeavor cohort 8 to evaluate enhanced immunosuppression regimen as part of Elevidys gene therapy for non-ambulant individuals with Duchenne	RE
16/03	Sarepta Announces That Screening and Enrollment Are Underway in Endeavor Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of Elevidys Gene Therapy for Non-Ambulant Individuals with Duchenne	CI

Douglas S. Ingram occupies the position of President, Chief Executive Officer & Director at Sarepta Therapeutics, Inc. He is also on the board of Allergan Foundation and Relay Therapeutics, Inc. He previously held the position of Attorney at Gibson, Dunn & Crutcher LLP, Chief Executive Officer & Director at Chase Pharmaceuticals Corp. and President for Allergan, Inc. Mr. Ingram received an undergraduate degree from Arizona State University and a graduate degree from the University of Arizona.

View full profile

Chart Sarepta Therapeutics, Inc.

Duration

Period

SRPT: Dynamic Chart

Company Profile

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.

Employees

835

Sector

Pharmaceuticals

More about the company